This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 ...

Facing another 61,000 unresolved lawsuits claiming its weedkiller causes cancer, Bayer added $1.2 billion to its glyphosate ...

Crop science giant Bayer says it has settled 17,000 glyphosate cases so far and hopes for a supreme court ruling next year.

Bayer has recently settled thousands of cases over claims the active ingredient in its Roundup weedkiller causes cancer, ...

The MAHA Commission itself has expressed concerns about glyphosate associated health risks in their May 2025 report on ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1100 ET – Bayer is expecting a historically high U.S. corn ...

BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

The reduction in Bayer's workforce under turnaround chief executive Bill Anderson has reached around 12,000 – a fall of ...

Bayer has cut more than one in 10 jobs since the launch of a sweeping restructuring programme aimed at streamlining decision-making and reducing layers of management.